Bibi Khoyratty, MD
Medical Oncology · Mason City, IANPI 1922077841
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $1,166 of the $1,485 with a category attached, or 78.5%. It is spread thinly across 11 manufacturers, the largest accounting for just 21.5% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2023 at $608 and has fallen 76.1% since, to $146 in 2025.
Across 22 payments — averaging $67.48 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Servier Pharmaceuticals LLC$319
- E.r. Squibb & Sons, L.L.C.$254
- Johnson & Johnson$182
- Lilly USA, LLC$137
- Amgen$125
- Mirati Therapeutics, Inc.$99
- plus $369 from 5 others
What the payments were for
- Food & beverage$1,16679%
- Education$31921%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Servier Pharmaceuticals LLC | 8 | $319 |
| E.r. Squibb & Sons, L.L.C. | 3 | $254 |
| Johnson & Johnson | 2 | $182 |
| Lilly USA, LLC | 2 | $137 |
| Amgen | 1 | $125 |
| Mirati Therapeutics, Inc. | 1 | $99 |
| AbbVie | 1 | $99 |
| Astellas Pharma US Inc | 1 | $97 |
| AstraZeneca | 1 | $91 |
| Incyte Corporation | 1 | $62 |
| Bayer | 1 | $20 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$1,485 in reported general payments places this provider in the 55th percentile of 47 medical oncology providers in Iowa.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| CalquenceAcalabrutinib Maleate | 16 | $245,644 |
| VenclextaVenetoclax | 19 | $105,314 |
| Abiraterone Acetate | 15 | $24,713 |
| EliquisApixaban | 14 | $7,830 |
| Exemestane | 24 | $3,955 |
| Letrozole | 82 | $975 |
| Prochlorperazine Maleate | 30 | $509 |
| Anastrozole | 28 | $442 |
| Ondansetron OdtOndansetron | 20 | $402 |
| Ondansetron Hcl | 43 | $378 |
| Acyclovir | 31 | $376 |
| Hydroxyurea | 22 | $361 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 15 | $341 |
| Tamoxifen Citrate | 18 | $312 |
| Dexamethasone | 17 | $299 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaCalquence | $91 | $245,64416 claims |
| AbbVieVenclexta | $99 | $105,31419 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 47 medical oncology providers in Iowa.
Other medical oncology in Mason City
- Natalia Ferrari GabilondoMason City$5K
- Louise CraggMason City$89
- Steven SnyderMason City$43
- Tara GraffClive$702K
- Jun ZhangIowa City$377K
- Mathew WehbeDes Moines$120K
- Ann StrohCedar Rapids$65K
- Praveen VikasFairfield$30K
- Giselle MeryDes Moines$12K
- John RiethIowa City$11K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.